DR-463 HYDRA: Integrative Molecular Characterization of Pancreatic and Esophagogastric Cancer for Personalized Treatment Optimization

Esophagogastric and pancreatic cancers are among the deadliest cancers, characterized by poor prognoses and limited treatment efficacy. Despite intensive research, previous efforts by our group to identify predictive molecular markers in esophagogastric cancer were not fully achieved. The HYDRA project seeks to fulfill these original goals, specifically targeting esophagogastric cancer, while also introducing a comprehensive integrative statistical model for both cancer types. This advanced model will combine diverse genomic and transcriptomic features to enhance the precision of predicting patient-specific outcomes and treatment responses, ultimately improving patient survival rates, quality of life, and optimizing therapeutic approaches through personalized medicine.

Hanneke van Laarhoven, VU Medical Center, Amsterdam UMC, the Netherlands